Creighton University

Nutech Ventures

Sandor Lovas

Nicholas Palermo

Laura Hansen

Istvan Teplan

Borbala Vincze

Geza Toth

Istvan Palyi

Adrienn Kalnay

Janos Seprodi

Imre Mezo

Zsolt Vadasz

J Michael Conlon

Magdolna Kovacs

Imre Mezom

Dezso Gaal

Gizella Turi

Melinda Mora

Richard F Murphy

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH(SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH(SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH(SEQ ID NO: 3).

14-3-3 targeting peptides for cancer treatment

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3&#x3b5; heterodimerization or CDC25A binding to 14-3-3&#x3b5;. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Ac-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Ala-Arg-NH(SEQ ID NO: 4) and a second targeting peptide comprising a structure of Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-NH(SEQ ID NO: 5), and a third targeting peptide comprising a modification of or a substituted derivative of the peptide of SEQ ID NO: 4 or SEQ ID NO: 5.

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3&#x3b5; heterodimerization or CDC25A binding to 14-3-3&#x3b5;. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH(SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH(SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH(SEQ ID NO: 3).

The present invention provides peptides and pharmacologically active compounds including gonadotropin-releasing hormone (GnRH) analogues according to formulas of the invention, wherein the compounds show an antitumor effect. The invention additionally provides compositions including these peptides and compounds.

GnRH analogues with antitumour effects and pharmaceutical compositions thereof

The present invention provides a novel pharmaceutical composition for the treatment of breast cancer. Also provided are various methods of treating breast cancer.

Anti-tumor effects of GnRH-III

Growing community of inventors

Omaha, NE, United States of America

Sandor Lovas